Epilepsy is a chronic disorder, characterized by unpredictable, uncontrolled seizures that interfere with lifestyles, activities, and interests. The condition introduces a number of psychosocial challenges and adaptive demands, threatening quality of life (QOL). Research investigating the impact of epilepsy on QOL has traditionally emphasized disease factors (e.g., seizure frequency and severity), treatment effectiveness (e.g., as produced by pharmacological agents or surgery), adverse effects of anti-epileptic drugs (AEDs), or complications of surgical treatment (e.g., for intractable seizures). In addition to factors directly attributable to the disease and/or its treatments, epilepsy introduces psychological and social stressors that affect ABSTRACT: Background: Chronic illnesses are associated with multiple stressors that compromise quality of life (QOL). Implicit in many of these stressors is the concept of illness intrusiveness: the disruption of lifestyles, activities, and interests due to the constraints imposed by chronic disease and its treatment. The purpose of this study was to examine illness intrusiveness and QOL in epilepsy in patients with different levels of seizure control. Methods: Cross-sectional data were obtained and compared between two groups of patients categorized by presence of seizures: seizure freedom or continued seizures (N=145). Standard instruments measured the following variables: illness intrusiveness, perceived personal control, subjective well-being, and disease specific QOL. Results: Illness intrusiveness varied inversely and significantly with seizure control. Complete seizure freedom, whether achieved by pharmacological or surgical treatment, was associated with the lowest levels of illness intrusiveness. Seizure freedom was also associated with increased perceived control, positive affect, self-esteem and QOL in epilepsy. Conclusions: The most robust benefits of decreased illness intrusiveness in epilepsy occur when treatment leads to complete seizure control. Therefore every effort should be made by health care providers to achieve seizure freedom to reduce illness intrusiveness and improve QOL in epilepsy.
of well-being. 1, 2 Some studies have highlighted stigmatization, a sense of loss of control, fear of seizures, social isolation and emotional difficulties that pose adaptive challenges. 3, 4 One study found significant correlations between adverse effects of AEDs and HRQOL, depression and HRQOL, and no correlation between seizure frequency and HRQOL. 5 However, the most consistently described determinant of self-reported QOL appears to be the degree of seizure control achieved. [5] [6] [7] [8] [9] Epilepsy clinicians and researchers have long recognized that seizure frequency compromises their patients' well-being. Those who are seizure free with pharmacological treatment report HRQOL levels similar to that observed in the general (physically healthy) population. 9 Studies of pharmacologically treated epilepsy consistently identify benefits in HRQOL, with the most substantial effects evident when patients achieve complete seizure freedom. More limited HRQOL benefits arise when patients achieve reduced seizure frequency, but not complete seizure freedom. 10, 11 Epilepsy surgery often results in significant reductions in seizure frequency. For many patients, anterior temporal lobectomy, the most common form of resective surgery, results in complete seizure freedom or limits occurrences to rare, isolated incidents. 12, 13 Studies evaluating the effectiveness of temporal lobectomy in patients with medically refractory seizures have, in general, demonstrated improved psychological functioning due to substantially reduced seizure frequency or complete seizure freedom. 6, 7, [14] [15] [16] [17] [18] [19] A recent study 20 identified the QOL domains that are important to persons with epilepsy treated with pharmacological agents with the aim of assessing the perceived impact of epilepsy on QOL. These questions were addressed using an open-ended survey approach among a community-based sample of 46 adults with epilepsy. The investigators inferred a multi-domain structure of QOL based on qualitative data analysis. Epilepsy was construed as having both a direct and an indirect impact on QOL by affecting QOL domains and by influencing factors that contributed to QOL. Frequently identified contributors (i.e., factors that preserve or enhance QOL) included social and family support, religion or spirituality, leisure, mental health, and employment. Addressing the detractors (i.e., factors that compromise QOL), such as psychological distress, worry of seizure occurrence, transportation limitations, and stigma, the investigators speculated that a number of factors directly associated with epilepsy affect the above-mentioned contributors. Detractors may directly influence one's willingness and/or ability to pursue employment or leisure activities, for example, and may influence social and family support. This approach is consistent with the Illness Intrusiveness theoretical framework. 21 The concept of illness intrusiveness relates to illness-induced disruptions to valued activities and interests that compromise QOL in chronic conditions, such as epilepsy. Illness intrusiveness has been conceptualized as a link between the circumstances of a disease and its treatment, on one hand, and subjective well-being, or QOL, on the other. [22] [23] [24] [25] The framework maintains that QOL is compromised to the extent that disease factors, such as seizure frequency, and treatment factors, such as pharmacological or surgical treatment for epilepsy, interfere with valued activities and interests, reducing the availability of rewarding experiences and personal control. 22 Evidence from diverse chronic disabling conditions has substantiated the illness intrusiveness framework in end-stage renal disease, 26, 27 multiple sclerosis, 23 rheumatoid arthritis, 23 breast cancer, 28 systemic lupus erythematosus, 25 psychiatric conditions, 29, 30 solid organ transplant recipients, 31, 32 sleep disorders 33 and epilepsy. 34 Gilliam and colleagues 35 showed that mood status and reported adverse medication side effects were significantly improved in patients following temporal lobe resection in epilepsy as compared to patients awaiting surgery. Lehrner et al 36 studied 56 consecutive patients with mesial temporal lobe epilepsy and assessed HRQOL and depression. These investigators found that depression was significantly and inversely correlated with HRQOL measures, even after controlling for seizure frequency, seizure severity and other psychosocial variables. However, the cross-sectional study of Lehrner and colleagues contained no seizure-free patients, and thus was unable to address the influence of seizure freedom on mood and HRQOL.
In this study, we examine the influence of complete versus incomplete seizure control on illness intrusiveness and HRQOL.
METHODS
The data for this analysis were obtained as part of a larger project investigating the theory of illness intrusiveness in epilepsy. 34 For the purposes of this study, a naturalistic crosssectional design was used to compare patients with different levels of seizure control, based on self-reported seizure frequency in the past year, categorized into two groups: seizurefree and continued seizures. This two-way categorization was chosen to be consistent with seizure frequency classifications previously reported in the relevant literature, where the most obvious differences found in QOL were between seizure-free patients and those who continued to have seizures. This categorization also parallels one of the most important comparative subclassifications of the Engel classification scheme 12 for seizure control after epilepsy surgery, where Class I = seizure free, and Classes II -IV represent progressively poorer control of seizures after surgical treatment. As part of the larger project, we also sub-classified the continued seizures group into patients with (a) < 3 seizures per year (equivalent to Class II in the Engel post-surgical scale), (b) 3 seizures per year to 5 seizures per month, and (c) ≥ 6 seizures per month, but concentrate in this study on the two-way grouping as potentially most relevant to QOL. Participants who were treated either pharmacologically or surgically were recruited from the Epilepsy Program at the Toronto Western Hospital, University Health Network, an academic tertiary care centre. Study sample size was estimated using the SPSS 37 Sample Power program. Relevant considerations included two groups categorized by presence of seizure, alpha of 0.05, power of 0.80, and a medium effect size for the Illness Intrusiveness Rating Scale (SD= 17.3). 38 Consecutive patients who satisfied the study inclusion and exclusion criteria were enrolled at the time of their followup appointments in the epilepsy clinic. All eligible patients (N=146) consented to participate in the study, yielding a response rate of 100%. One patient was excluded from the study following the diagnosis of nonepileptic seizures, resulting in a total sample of 145 patients, divided into two groups. Group one included seizure-free patients, and the second group included patients who continued to have seizures. Of these, 92 (63.4%) were pharmacologically treated and 53 (36.6%) had been treated surgically for medically refractory epilepsy. The pharmacologically treated patients included patients whose seizures were satisfactorily controlled with AEDs, patients with medically refractory epilepsy awaiting testing to determine surgical candidacy, and patients who were already determined not to be surgical candidates based on epilepsy syndrome (e.g., primary generalized epilepsy; symptomatic generalized epilepsy and multi-focal epilepsies). The surgically treated patients had previously undergone resective surgery as a treatment for medically refractory epilepsy. For the purposes of this study, the four characteristics (seizure frequency, employment status, current number of AEDs, and side effects of AEDs) that correlated with the concepts of interest (i.e., illness intrusiveness and HRQOL) were retained as covariates (further discussed in Covariate Identification section).
Procedure
Following approval by the institutional Research Ethics Board, the neurologist (RW) identified consecutive eligible patients, who satisfied the study inclusion and exclusion criteria. The investigator subsequently contacted the patients, explained the study and administered the questionnaires after obtaining informed consent. Participants completed the questionnaires in a private room within the clinic.
Inclusion and exclusion criteria
Patients with epilepsy were eligible for inclusion in the study if they were 18 years-of-age or older and able to communicate in the English language. Pharmacologically treated patients were those whose treatment was stabilized no less than one year prior to participation in the study. All surgical patients who participated in this study represented individuals who had undergone surgery at least one year before completing the study materials. Prospective participants were excluded if they had secondary medical diagnoses that might contribute to illness intrusiveness, such as cancer, diabetes, heart disease or hypertension.
MATERIALS/MEASURES AND METHODS
The self-report questionnaires contained standard instruments measuring the variables of interest: illness intrusiveness, perceived personal control, subjective well-being, and disease specific (epilepsy) HRQOL.
Illness Intrusiveness was measured by the Illness Intrusiveness Ratings Scale (IIRS). 21 The IIRS is a 13-item selfreport instrument in which individuals rate the extent to which their illness and/or its treatment interfere with each of 13 life domains relevant to QOL, 39 such as health, work, personal life and social life. The IIRS uses a 7-point rating scale, ranging from 1 = Not Very Much to 7 = Very Much, to measure the degree of lifestyle interference attributable to disease and/or treatment factors.
Personal Control was measured by the Control Ratings Scale. 21 This questionnaire entails 13 items asking patients how much control they have over the same 13 life domains covered in the IIRS.
Two complimentary approaches were used to measure QOL: subjective well-being and disease specific (epilepsy) healthrelated quality of life (HRQOL). Four instruments were administered to assess complementary dimensions of subjective well-being (including psychological well-being and emotional distress) because no single instrument provides a comprehensive assessment of these diverse, subtly distinctive facets of QOL. 40 Psychological well-being was assessed using the following three widely established self-report instruments: Affect Balance Scale 41 (ABS), Atkinson Life Happiness Rating Scale, 42 and Rosenberg Self-Esteem Inventory. 43 The ABS is a well-validated measure of psychological wellbeing that has been used extensively in physically healthy and various illness populations. 41 It includes two subscales measuring positive (Positive Affect Subscale, PAS) and negative mood (Negative Affect Subscale, NAS). Each subscale consists of five binary (Yes/No) items to indicate the mood state during the preceding week.
The Atkinson Life Happiness Rating Scale is a single-item assessing overall happiness in life. It consists of an 11-point numeric rating scale ranging from 1 (very unhappy) through 6 (an even mixture of unhappiness and happiness) to 11 (very happy). The instrument's psychometric adequacy has been established in previous investigations. 23, 26, 27 Self-Esteem was measured by the Rosenberg Self-Esteem Inventory, a self-administered scale that asks respondents whether they agree or disagree with ten statements about selfworth. The range of possible scores is from 10 to 40, with higher scores indicating higher levels of self-esteem. Strong evidence supports its reliability and validity. 44 The scale has an internal consistency reliability of 0.92 and test-retest correlations of 0.85 and 0.88 over two weeks.
Emotional distress was assessed by the Center for Epidemiologic Studies Depression (CES-D) Scale. 45 It is a 20-item self-administered questionnaire designed to measure depressive symptomatology in the general (i.e., non-psychiatric) population, addressing the frequency with which one has experienced depressive symptoms during the preceding week. It uses a 4-point forced-choice response format, ranging from 0, "rarely or none of the time, to 3, "most or all of the time. It has high internal consistency reliability (Cronbach's alpha 0.84 to 0.90). All of these instruments have been widely used in physically healthy and ill populations and their psychometric adequacy has been established in previous investigations.
Health-Related Quality of Life was evaluated by the Quality of Life in Epilepsy (QOLIE) Scale, 46 a 10-item questionnaire (QOLIE-10) for screening patients with epilepsy about the impact of the epilepsy on their lives. It entails a subset of items from the more extensive QOLIE-89. 47 Total QOLIE-10 scores range from 5 to 50. High scores indicate poor QOL. The QOLIE-10 was selected as a measure of HRQOL because it is brief, simple, and can be completed quickly by patients.
RESULTS

Demographic characteristics
Demographic characteristics for the study sample are presented in Table 1 . The results of group comparisons indicated differences only in education level attained. A larger percentage of patients in the continued seizures group had attended college the lone variable retained as a covariate for analyses involving affect balance, self-esteem, happiness and depression. Analysis of covariance (ANCOVA) compared the two patient groups based on presence vs. absence of seizures.
Seizure control and illness intrusiveness
Patients in the two seizure group categories (seizure-free and continued seizures) differed significantly in illness intrusiveness (t-value = 5.30, df= 143, p< 0.01) ( Table 3) . Those who were seizure-free reported lower levels of illness intrusiveness than those with continued seizures.
Seizure control and psychosocial outcomes
The same analytic strategy (ANCOVA) was employed for each of the psychosocial outcome variables, including personal control, depression, happiness, self-esteem, positive and negative affect and QOLIE. Table 3 reports the adjusted means for each of the QOL variables. All psychosocial outcomes differed significantly between the seizure-free and continued seizure groups. Seizure freedom, whether achieved with pharmacological or surgical treatment, was associated with the lowest illness intrusiveness and depression scores, and with increased control, happiness, self-esteem, positive affect and QOLIE scores. The seizure-free group reported lower levels of depression and negative affect, and higher levels of perceived control over diverse domains of life, higher levels of happiness, self-esteem, positive affect and QOLIE (note that increasing scores on the QOLIE-10 scale indicate decreasing QOL).
DISCUSSION
Epilepsy is a chronic disorder, characterized by unpredictable, uncontrolled seizures and physiological changes, or university as compared to the seizure-free group (56% versus 48%). There were no other statistically significant differences between the two groups with respect to other demographic characteristics. The clinical characteristics of the two groups of patients representing presence of seizure are illustrated in Table  2 . Over half of the study participants (57%) were experiencing simple partial, complex partial, and secondarily generalized seizures. Approximately 12% of participants were experiencing simple partial and complex partial seizures only and 13% were experiencing complex partial and secondarily generalized seizures, without simple partial seizures. Approximately 12% of the pharmacologically treated patients had primary generalized epilepsy with generalized motor seizures.
Covariate identification
The larger overall project from which this study is derived included comparative assessments of patients separated by treatment (pharmacological or surgical) modalities. Potential confounding variables were initially identified based on published findings and clinical experience. Covariates were retained for statistical control based on bivariate correlational analyses among a number of background characteristics (e.g. age, gender, marital status, education, employment, epilepsy duration, number of current AEDs, number of AED-related side effects, seizure frequency), Illness Intrusiveness scores, and the other psychosocial measures (e.g., QOLIE, depression, selfesteem, control, affect balance, happiness). With respect to Illness Intrusiveness, four characteristics were significantly correlated at the p < 0.01 level: AED side effects (r = 0.21), current number of AEDs (r = 0.24), employment (r = -0.33) and seizure frequency (r = 0.70). For QOL, the same four variables correlated significantly (rs = 0.24, 0.27, -0.32 and 0.57). Forward stepwise multiple regression analyses reduced the number of covariates to the smallest non-redundant set. This led us to retain the four above-mentioned variables as covariates for Illness Intrusiveness, QOLIE and control. Seizure frequency was 3, 48, 49 this study was the first to compare the impact of seizure control on illness intrusiveness and QOL in epilepsy.
The results are consistent with earlier studies that showed that illness intrusiveness is associated with decreased QOL in different patient populations with other chronic conditions, such as end-stage renal disease, multiple sclerosis, rheumatoid arthritis, breast cancer, systemic lupus erythematosus, and various psychiatric disorders. [21] [22] [23] [24] [25] [26] [27] [28] [29] Conceptualized as a facet of the chronic disease experience that is common across conditions, illness intrusiveness is viewed as a mediating variable intervening between the objective circumstances of disease and treatment on the one hand, and subjective well-being or HRQOL on the other. 22 The illness intrusiveness model holds that QOL is compromised to the extent that disease and treatment factors interfere with valued activities and interests, reducing the availability of rewarding experiences and personal control. 22 The illness intrusiveness framework appears valid in epilepsy, 34 as it has been in other chronic conditions.
Illness intrusiveness can be decreased either by reducing the burden of disease and treatment factors or by moderating contributory psychosocial (e.g., cultural stigma) factors. 21 From the results of this study it can be seen that in epilepsy medical or surgical interventions resulting in seizure freedom (i.e., eradication of disease burden) are significantly associated with lower levels of illness intrusiveness. Seizure freedom was also associated with lower rates of depression, as well as benefits in terms of perceived personal control, happiness, self-esteem, positive affect and HRQOL. The HRQOL findings are consistent with previous reports documenting the benefits of seizure freedom in patients with epilepsy. [6] [7] [8] [9] The validity of this interpretation is supported by the fact that the observed benefits of seizure freedom were evident for all of the psychosocial and QOL measures we examined.
Drawing from experience with other chronic conditions, it might be possible to decrease illness intrusiveness in patients with epilepsy through interventions aimed at improving psychosocial factors (e.g., eradicating cultural stigma, or improving self-concept or disease-related knowledge through psychotherapy 50 or psychoeducation 51 ), interventions that would specifically target the illness intrusiveness stressor with the aim of decreasing its negative impact upon QOL (e.g., behavioral self-management programs 52 ). Psychosocial interventions might be especially beneficial for medically refractory epilepsy patients who are not candidates for surgical treatment. In this regard, we plan to undertake future studies that include such psychosocial interventions specifically targeting illness intrusiveness.
Although the illness intrusiveness framework has been validated repeatedly and in various conditions, it must be acknowledged that a certain degree of overlap between illness intrusiveness and HRQOL is to be expected simply on the basis of the types of items explored in the respective questionnaires. This is more of a concern for instruments such as the QOLIE or the SF-36, 53 because they include items that tap interference with roles and activities, than it is for measures of subjective wellbeing, such as measures of depression, happiness, or self-esteem because these tap independent concepts. With respect to depression, the situation is potentially more complicated in epilepsy than other chronic conditions given the possibility of a direct biological link between epilepsy and depression, although the evidence supporting this biological association is admittedly equivocal. 54 Future work will need to address these issues.
In this study group, approximately 62% of the post-surgical patients reported being seizure free. These results are consistent with previous studies, substantiating the representativeness of the current research sample with respect to the post surgical patients. For example, Brodie and Leach 55 reported 60% to 70% seizure freedom following temporal lobectomy and Wiebe and colleagues 8 reported 58% seizure freedom one year post-surgery. However, seizure freedom in the pharmacologically treated patients was only 15%, lower than the typically reported 60% to 70% seizure freedom rate in the epilepsy population as a whole, which is almost certainly a reflection of the overrepresentation of patients with medically-refractory epilepsy at a tertiary referral centre. Despite the limitations of small sample size and reliance on self-report questionnaires, the present results provide additional support that the most important benefits of increased QOL (and of decreased illness intrusiveness) in epilepsy occur when treatment leads to complete seizure control. It would appear that illness intrusiveness might be reduced by either of the treatment modalities we examined (i.e., pharmacological or surgical) so long as improved seizure control is the result. Every effort should be made by health care providers to strive for a seizure free outcome in patients with epilepsy, to reduce illness intrusiveness and improve QOL.
